Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Britain Courts Anthropic Amid US Defense Department Dispute 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
EXTON, Pa., Aug. 03, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that John Maslowski, President and Chief Executive Officer, will present at the Canaccord Genuity 37th Annual Growth Conference on Thursday, August 10 at 2:30 pm EDT in Boston, Massachusetts.
A live webcast of Fibrocell’s presentation will be available under the investor relations section of the Company’s website at www.fibrocell.com/investors/events and archived for 30 days. Please visit Fibrocell’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE: XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact: Karen Casey 484.713.6133 [email protected]
